盘中异动 | 药明巨诺-B盘中上涨8%,报于3.97港元
2022年11月14日9时42分,药明巨诺-B(HK02126)盘中上涨8%,报于3.97港元,成交额达48.22万港元,换手率达到0.01%。
10月11日讯,药明巨诺-B(02126.HK)公布,国家药监局已批准其靶向CD19的自体嵌合抗原受体T(CAR-T)细胞免疫治疗产品瑞基奥仑赛注射液(倍诺达)的新适应症上市许可申请,用于治疗经过二线或以上系统性治疗的成人难治性或24个月内复发的滤泡性淋巴瘤(r/rFL)。
盈立趋势长盈模型最近一次交易信号,2022年11月11日出现关注信号,触发价格为3.67港元(信号仅供参考)。
uSMART智能写手的信息、数据均来自媒体公开报道,智能写手不能保证其完全准确,内容仅供参考,不构成投资建议。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.